Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease.
暂无分享,去创建一个
D. Pennington | M. D. Turner | B. Nedjai | T. Hurst | Daniel J Pennington | Mark D Turner | Belinda Nedjai | Tara Hurst | Tara Hurst
[1] D. MacEwan. TNF receptor subtype signalling: differences and cellular consequences. , 2002, Cellular signalling.
[2] Dong-Kug Choi,et al. Blockade of Microglial Activation Is Neuroprotective in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson Disease , 2002, The Journal of Neuroscience.
[3] H. Yazici,et al. Acute phase response in familial Mediterranean fever , 2002, Annals of the rheumatic diseases.
[4] D. Männel,et al. The TNFTNF Receptor System , 2002 .
[5] J. Loike,et al. Scavenger receptor-mediated adhesion of microglia to β-amyloid fibrils , 1996, Nature.
[6] E. Bézard,et al. Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease , 2004, The European journal of neuroscience.
[7] S. Akıncı,et al. Serum sIL-2r, IL-6, IL-10 and TNF-α level in familial Mediterranean fever patients , 2003, Clinical Rheumatology.
[8] R. Locksley,et al. The TNF and TNF Receptor Superfamilies Integrating Mammalian Biology , 2001, Cell.
[9] W. Brück,et al. Additive microglia-mediated neuronal injury caused by amyloid-β and bacterial TLR agonists in murine neuron-microglia co-cultures quantified by an automated image analysis using cognition network technology. , 2012, Journal of Alzheimer's disease : JAD.
[10] D. Largaespada,et al. Lymphotactin: a cytokine that represents a new class of chemokine. , 1994, Science.
[11] L. Mayer,et al. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease , 2010, Expert review of clinical immunology.
[12] G. Hitman,et al. Proinflammatory action of the antiinflammatory drug infliximab in TNF-receptor associated periodic syndrome , 2009 .
[13] J. Gauldie,et al. IFNβ2/BSF2/IL‐6 Is the Monocyte‐derived HSF That Regulates Receptor‐specific Acute Phase Gene Regulation in Hepatocytes a , 1989, Annals of the New York Academy of Sciences.
[14] K. Suk,et al. IFN-γ/TNF-α Synergism as the Final Effector in Autoimmune Diabetes: A Key Role for STAT1/IFN Regulatory Factor-1 Pathway in Pancreatic β Cell Death1 , 2001, The Journal of Immunology.
[15] I. Ceccherini,et al. A novel mutation in the CIAS1/NLRP3 gene associated with an unexpected phenotype of cryopyrin-associated periodic syndromes. , 2014, Clinical and experimental rheumatology.
[16] T. Di Paolo,et al. Differential Protective Properties of Estradiol and Tamoxifen against Methamphetamine-Induced Nigrostriatal Dopaminergic Toxicity in Mice , 2006, Neuroendocrinology.
[17] S. Segerer,et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity , 2009, Nature Immunology.
[18] D. Zemer,et al. Activation of the cytokine network in familial Mediterranean fever. , 1999, The Journal of rheumatology.
[19] N. Borregaard,et al. Neutrophil granules and secretory vesicles in inflammation. , 2003, Microbes and infection.
[20] N. Osada,et al. Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history , 2012, Genes to cells : devoted to molecular & cellular mechanisms.
[21] Wei Wang,et al. A new class of membrane-bound chemokine with a CX3C motif , 1997, Nature.
[22] T. Kishimoto. IL-6: from its discovery to clinical applications. , 2010, International immunology.
[23] Terry Farrah,et al. The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death , 1994, Cell.
[24] J. Lafitte,et al. Expression of IFN-gamma-inducible protein; monocyte chemotactic proteins 1, 3, and 4; and eotaxin in TH1- and TH2-mediated lung diseases. , 2001, The Journal of allergy and clinical immunology.
[25] C. Luo,et al. CXCL17, an orphan chemokine, acts as a novel angiogenic and anti-inflammatory factor. , 2013, American journal of physiology. Endocrinology and metabolism.
[26] M. Haneklaus,et al. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. , 2013, Current opinion in immunology.
[27] M. Zeher,et al. Serum and urinary cytokine levels of SLE patients. , 2012, Die Pharmazie.
[28] J. Tschopp,et al. Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.
[29] M. Leirisalo-Repo. The present knowledge of the inflammatory process and the inflammatory mediators. , 1994, Pharmacology & toxicology.
[30] M. Sporn,et al. The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection , 2008, Journal of Neuroinflammation.
[31] A. Członkowska,et al. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). , 1998, Immunopharmacology.
[32] S. Paul,et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[33] B. Chromy,et al. Amyloid-β peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release , 1998, Brain Research.
[34] M. Pras,et al. Clinical disease among patients heterozygous for familial Mediterranean fever. , 2009, Arthritis and rheumatism.
[35] D. Häussinger,et al. Caspase-mediated cleavage of the signal-transducing IL-6 receptor subunit gp130. , 2008, Archives of biochemistry and biophysics.
[36] P Barton,et al. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. , 2004, Health technology assessment.
[37] P. Taupin. Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells , 2008, International journal of medical sciences.
[38] Zheng‐gang Liu,et al. The function of TRADD in signaling through tumor necrosis factor receptor 1 and TRIF-dependent Toll-like receptors , 2008, Nature Immunology.
[39] Yoshiya Tanaka. Next stage of RA treatment: is TNF inhibitor-free remission a possible treatment goal? , 2012, Annals of the rheumatic diseases.
[40] C. Abraham. Reactive astrocytes and α1-antichymotrypsin in Alzheimer’s disease ☆ ☆ Supported by the NIH and the Alzheimer’s Association. , 2001, Neurobiology of Aging.
[41] M. Feldmann,et al. Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.
[42] A. Sidhu,et al. Inflammation and Parkinson's disease. , 2002, Current drug targets. Inflammation and allergy.
[43] Rena Li,et al. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain , 1997, Brain Research.
[44] M. Eberhardson,et al. Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis. , 2013, Clinical immunology.
[45] M. Pillinger,et al. Interleukin-6 in the pathogenesis of rheumatoid arthritis. , 2007, Bulletin of the NYU hospital for joint diseases.
[46] Caroline A Sabin,et al. Natural history and outcome in systemic AA amyloidosis. , 2007, The New England journal of medicine.
[47] M. Matthay,et al. Elevated levels of NAP-1/interleukin-8 are present in the airspaces of patients with the adult respiratory distress syndrome and are associated with increased mortality. , 1992, The American review of respiratory disease.
[48] Shyamasree Ghosh,et al. C-reactive protein and the biology of disease , 2013, Immunologic Research.
[49] Y Agid,et al. Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[50] Wenjie Xie,et al. Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease , 2001, The Journal of Neuroscience.
[51] Fiona C. Kimberley,et al. Disease causing mutations in the TNF and TNFR superfamilies: Focus on molecular mechanisms driving disease. , 2011, Trends in molecular medicine.
[52] M. Miura,et al. Neurotoxic Effects of Lipopolysaccharide on Nigral Dopaminergic Neurons Are Mediated by Microglial Activation, Interleukin-1β, and Expression of Caspase-11 in Mice* , 2004, Journal of Biological Chemistry.
[53] D. Kastner,et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. , 2008, Arthritis and rheumatism.
[54] T. Kishimoto,et al. Gp130 and the interleukin-6 family of cytokines. , 1997, Annual review of immunology.
[55] Sudhir Gupta,et al. Tumor necrosis factor-α-induced apoptosis in T cells from aged humans: a role of TNFR-I and downstream signaling molecules , 2002, Experimental Gerontology.
[56] C. Hawkey,et al. Enhanced synthesis of neutrophil-activating peptide-1/interleukin-8 in active ulcerative colitis. , 1992, Clinical science.
[57] H. Joller-jemelka,et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. , 2002, The Journal of clinical investigation.
[58] R L Kassel,et al. An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[59] E. Ben-Chetrit,et al. Familial mediterranean fever and Behçet's disease--are they associated? , 2002, The Journal of rheumatology.
[60] M. Satoh,et al. Apoptosis of cultured microglia by the deprivation of macrophage colony-stimulating factor , 1996, Neuroscience Research.
[61] C. Ware,et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. , 1998, Journal of immunology.
[62] A. Bowie,et al. Activation of host pattern recognition receptors by viruses. , 2010, Current opinion in microbiology.
[63] L. Mayer,et al. Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update , 2013, Expert review of clinical immunology.
[64] M. Delgado,et al. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[65] James C. Powell,et al. Interleukin-1 Receptor Type 1 Is a Substrate for γ-Secretase-dependent Regulated Intramembrane Proteolysis* , 2009, Journal of Biological Chemistry.
[66] M. Baggiolini,et al. Monocyte chemotactic proteins MCP‐1, MCP‐2, and MCP‐3 are major attractants for human CD4+ and CD8+ T lymphocytes , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[67] G. Gualdi,et al. Recurrent migratory angioedema as cutaneous manifestation in a familiar case of TRAPS: dramatic response to Anakinra. , 2013, Dermatology online journal.
[68] H. Mitsumoto,et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial , 2007, The Lancet Neurology.
[69] H. Ichinose,et al. Cytokines in Parkinson’s Disease , 2000 .
[70] K. Garber. Pfizer's first-in-class JAK inhibitor pricey for rheumatoid arthritis market , 2013, Nature Biotechnology.
[71] Andrew G. D. Bean,et al. TNF Regulates Chemokine Induction Essential for Cell Recruitment, Granuloma Formation, and Clearance of Mycobacterial Infection1 , 2002, The Journal of Immunology.
[72] G. Arendash,et al. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease , 2009, Glia.
[73] B. Bradt,et al. Constitutive expression of proinflammatory complement components by subsets of neurons in the central nervous system , 2002, Journal of Neuroimmunology.
[74] G. Yancopoulos,et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. , 2008, Arthritis and rheumatism.
[75] R. Powell,et al. Clinical spectrum of familial Hibernian fever: a 14-year follow-up study of the index case and extended family. , 1997, Mayo Clinic proceedings.
[76] M. Johnstone,et al. A central role for astrocytes in the inflammatory response to β-amyloid; chemokines, cytokines and reactive oxygen species are produced , 1999, Journal of Neuroimmunology.
[77] L. Ginsberg,et al. Neurologic manifestations of the cryopyrin-associated periodic syndrome , 2010, Neurology.
[78] J. Loike,et al. Scavenger receptor-mediated adhesion of microglia to beta-amyloid fibrils. , 1996, Nature.
[79] Y. Iwakura,et al. A role for leukocyte-derived IL-1RA in DC homeostasis revealed by increased susceptibility of IL-1RA-deficient mice to cutaneous leishmaniasis. , 2011, The Journal of investigative dermatology.
[80] E. Posse de Chaves,et al. Aβ Internalization by Neurons and Glia , 2011, International journal of Alzheimer's disease.
[81] M. Feldmann,et al. Anti-TNF Therapy, from Rationale to Standard of Care: What Lessons Has It Taught Us? , 2010, The Journal of Immunology.
[82] S. Hunot,et al. Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.
[83] T. Town,et al. Neuronal expression of CD22: Novel mechanism for inhibiting microglial proinflammatory cytokine production , 2004, Glia.
[84] R. Vassar,et al. The contribution of activated astrocytes to Aβ production: Implications for Alzheimer's disease pathogenesis , 2011, Journal of Neuroinflammation.
[85] A. Hamzaoui,et al. Levels of IL‐15 in Serum and Cerebrospinal Fluid of Patients with Behçet's Disease , 2006, Scandinavian journal of immunology.
[86] R. Vink,et al. Recent patents in CNS drug discovery: the management of inflammation in the central nervous system. , 2009, Recent patents on CNS drug discovery.
[87] C. von Kalle,et al. Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease. , 1991, Blood.
[88] Sara Hall,et al. Cerebrospinal fluid inflammatory markers in Parkinson’s disease – Associations with depression, fatigue, and cognitive impairment , 2013, Brain, Behavior, and Immunity.
[89] R. Vaughan,et al. Behçet’s disease: from Hippocrates to the third millennium , 2003, The British journal of ophthalmology.
[90] P. Scheurich,et al. Coexpression of the human TNF receptors TR60 and TR80 in insect cells: analysis of receptor complex formation. , 1994, Lymphokine and cytokine research.
[91] D. Kioussis,et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.
[92] M. Feldmann,et al. INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.
[93] Wan-Wan Lin,et al. Silymarin protects dopaminergic neurons against lipopolysaccharide‐induced neurotoxicity by inhibiting microglia activation , 2002, The European journal of neuroscience.
[94] M. Thelen,et al. Dancing to the tune of chemokines , 2001, Nature Immunology.
[95] Miss A.O. Penney. (b) , 1974, The New Yale Book of Quotations.
[96] D. Ota,et al. Angiogenic Effects of Interleukin 8 (CXCL8) in Human Intestinal Microvascular Endothelial Cells Are Mediated by CXCR2* , 2003, The Journal of Biological Chemistry.
[97] R. Mrak,et al. Interleukin-1, neuroinflammation, and Alzheimer’s disease , 2001, Neurobiology of Aging.
[98] Howard E. Gendelman,et al. Selective inhibition of NF-κB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease , 2007, Proceedings of the National Academy of Sciences.
[99] E. Hauben,et al. SPPL2a and SPPL2b promote intramembrane proteolysis of TNFα in activated dendritic cells to trigger IL-12 production , 2006, Nature Cell Biology.
[100] B. Botterman,et al. Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease , 2006, The Journal of Neuroscience.
[101] M. Krane,et al. Chemokines indicate allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. , 2006, American journal of respiratory and critical care medicine.
[102] J. Casanova,et al. Human TLRs and IL-1Rs in host defense: natural insights from evolutionary, epidemiological, and clinical genetics. , 2011, Annual review of immunology.
[103] Kate Schroder,et al. The NLRP3 Inflammasome: A Sensor for Metabolic Danger? , 2010, Science.
[104] R. Sartor. Cytokines in Intestinal Inflammation: Clinical Considerations , 1994 .
[105] M. Karow,et al. The Eotaxin Chemokines and CCR3 Are Fundamental Regulators of Allergen-Induced Pulmonary Eosinophilia1 , 2005, The Journal of Immunology.
[106] S. Akira,et al. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.
[107] J. Verhoef,et al. Amyloid-β-induced chemokine production in primary human macrophages and astrocytes , 2002, Journal of Neuroimmunology.
[108] B. Medoff,et al. IFN-gamma-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. , 2002, Journal of immunology.
[109] Mark P. Mattson,et al. NF-κB in the Survival and Plasticity of Neurons , 2005, Neurochemical Research.
[110] A. Plebani,et al. Favourable and sustained response to anakinra in tumour necrosis factor receptor-associated periodic syndrome (TRAPS) with or without AA amyloidosis , 2010, Annals of the rheumatic diseases.
[111] E. Tindall,et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.
[112] T. Wright,et al. Endogenous IL-1α from systemic sclerosis fibroblasts induces IL-6 and PDGF-A , 1999 .
[113] S. Targan,et al. A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .
[114] Hong-Wei Sun,et al. Homeostatic Tissue Responses in Skin Biopsies from NOMID Patients with Constitutive Overproduction of IL-1β , 2012, PloS one.
[115] M. Pepys,et al. Acute phase response and evolution of familial Mediterranean fever. , 1999, Lancet.
[116] Saumya Das,et al. Effect of cytokines, dexamethazone and the A/T-signal peptide polymorphism on the expression of alpha1-antichymotrypsin in astrocytes: significance for Alzheimer's disease , 2001, Neurochemistry International.
[117] L. Piccio,et al. Chemokines trigger immediate beta2 integrin affinity and mobility changes: differential regulation and roles in lymphocyte arrest under flow. , 2000, Immunity.
[118] İ. Tuğal-Tutkun,et al. Pro-inflammatory cellular immune response in Behçet’s disease , 2007, Rheumatology International.
[119] M. Sporn,et al. Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription , 2009, PloS one.
[120] K. Nadeau,et al. XCL1 Enhances Regulatory Activities of CD4+CD25highCD127low/− T Cells in Human Allergic Asthma1 , 2008, The Journal of Immunology.
[121] J. Lindenmann,et al. Virus interference. I. The interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.
[122] P. Lipsky,et al. Chemokine receptor expression and functional effects of chemokines on B cells: implication in the pathogenesis of rheumatoid arthritis , 2009, Arthritis research & therapy.
[123] Han-Chang Huang,et al. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer's disease. , 2009, Journal of Alzheimer's disease : JAD.
[124] E. Hirsch,et al. Protective action of the peroxisome proliferator‐activated receptor‐γ agonist pioglitazone in a mouse model of Parkinson's disease , 2002, Journal of neurochemistry.
[125] W. Kohr,et al. Human tumor necrosis factor. , 1985, Methods in enzymology.
[126] P. Hawkins,et al. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. , 2003, The New England journal of medicine.
[127] M. Pepys,et al. Acute phase response and evolution of familial Mediter ranean fever , 1999, The Lancet.
[128] E. Tolosa,et al. Parkinson disease: New guidelines for diagnosis of Parkinson disease , 2013, Nature Reviews Neurology.
[129] D. Farfara,et al. Neuroprotective and neurotoxic properties of glial cells in the pathogenesis of Alzheimer's disease , 2008, Journal of cellular and molecular medicine.
[130] M. Tansey,et al. Neuroinflammatory mechanisms in Parkinson's disease: Potential environmental triggers, pathways, and targets for early therapeutic intervention , 2007, Experimental Neurology.
[131] B. Molnár,et al. Changes of the cytokine profile in inflammatory bowel diseases. , 2012, World journal of gastroenterology.
[132] J. Lindenmann,et al. Virus interference. I. The interferon. , 1987, Proceedings of the Royal Society of London. Series B, Biological sciences.
[133] J. Cano,et al. Minocycline reduces the lipopolysaccharide-induced inflammatory reaction, peroxynitrite-mediated nitration of proteins, disruption of the blood–brain barrier, and damage in the nigral dopaminergic system , 2004, Neurobiology of Disease.
[134] M. Delgado,et al. Vasoactive intestinal peptide prevents activated microglia‐induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[135] D. Perl,et al. Aggresome‐related biogenesis of Lewy bodies , 2002, The European journal of neuroscience.
[136] W. Friedman. Cytokines Regulate Expression of the Type 1 Interleukin-1 Receptor in Rat Hippocampal Neurons and Glia , 2001, Experimental Neurology.
[137] M. Mattson,et al. Roles for NF-kappaB in nerve cell survival, plasticity, and disease. , 2006, Cell death and differentiation.
[138] C. Abraham. Reactive astrocytes and alpha1-antichymotrypsin in Alzheimer's disease. , 2001, Neurobiology of aging.
[139] H. Koeffler,et al. Hematopoietic-specific expression of MEFV, the gene mutated in familial Mediterranean fever, and subcellular localization of its corresponding protein, pyrin. , 2000, Blood.
[140] Ole Isacson,et al. Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease , 2004, Journal of Neuroinflammation.
[141] L. Lue,et al. Microglial chemotaxis, activation, and phagocytosis of amyloid β-peptide as linked phenomena in Alzheimer's disease , 2001, Neurochemistry International.
[142] J. Julien,et al. Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease , 2006, Neuron.
[143] M. Duvdevani,et al. Expansion of γδ T-cells in Behçet's disease: Role of disease activity and microbial flora in oral ulcers , 2003 .
[144] S. Holland,et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.
[145] W. Le,et al. Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum , 2001, Brain Research.
[146] J. Woody,et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.
[147] R. Valentine,et al. Virus interference. II. Some properties of interferon , 1957, Proceedings of the Royal Society of London. Series B - Biological Sciences.
[148] M. Feldmann,et al. Anti-TNF Therapy. , 2016, Microbiology spectrum.
[149] K. Rajarathnam,et al. Diverging Mechanisms of Activation of Chemokine Receptors Revealed by Novel Chemokine Agonists , 2011, PloS one.
[150] R M Siegel,et al. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. , 2000, Science.
[151] J. Cano,et al. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh-TNF-alpha, IL-1beta and IFN-gamma. , 2002, Journal of neurochemistry.
[152] M. Baggiolini,et al. Neutrophil activation and the effects of interleukin-8/neutrophil-activating peptide 1 (IL-8/NAP-1). , 1992, Cytokines.
[153] A. Peled,et al. Critical Involvement of the Chemotactic Axis CXCR4/Stromal Cell-Derived Factor-1α in the Inflammatory Component of Allergic Airway Disease , 2000, The Journal of Immunology.
[154] A. Cope,et al. Enhanced expression of tumor necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints , 1992, European journal of immunology.
[155] A. Antonini,et al. EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease , 2013, European journal of neurology.
[156] C. Kaltschmidt,et al. Signaling via NF-?B in the nervous system , 2005 .
[157] B. Dijkmans,et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. , 2005, Arthritis and rheumatism.
[158] M. Baggiolini. Chemokines in pathology and medicine , 2001, Journal of internal medicine.
[159] M. Alonso,et al. Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells , 2012, Journal of neuroscience research.
[160] Jau-Shyong Hong,et al. Transcriptional Factor NF-κB as a Target for Therapy in Parkinson's Disease , 2011, Parkinson's disease.
[161] T. Chase,et al. NF-κB contributes to 6-hydroxydopamine-induced apoptosis of nigral dopaminergic neurons through p53 , 2007, Brain Research.
[162] M. Neurath,et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. , 2001, European journal of biochemistry.
[163] H. Rosenzweig,et al. Impact of IL-1 signalling on experimental uveitis and arthritis , 2012, Annals of the rheumatic diseases.
[164] K. Matsushima,et al. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. , 1989, Journal of immunology.
[165] C. Elson,et al. Experimental models of inflammatory bowel disease. , 1995, Gastroenterology.
[166] J. Lannigan,et al. Analysis of CD25hiCD4+ "regulatory" T-cell subtypes in atopic dermatitis reveals a novel T(H)2-like population. , 2008, The Journal of allergy and clinical immunology.
[167] John Hardy,et al. Parkinson's disease , 2009, The Lancet.
[168] E. Sohar,et al. [Familial Mediterranean fever]. , 1955, Acta geneticae medicae et gemellologiae.
[169] W. Arend,et al. Biological role of interleukin 1 receptor antagonist isoforms , 2000, Annals of the rheumatic diseases.
[170] B. Liu,et al. Dextromethorphan Protects Dopaminergic Neurons against Inflammation-Mediated Degeneration through Inhibition of Microglial Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.
[171] G. Hitman,et al. A novel TNFRSF1A splice mutation associated with increased nuclear factor κappaB (NF-κB) transcription factor activation in patients with tumour necrosis factor receptor associated periodic syndrome (TRAPS) , 2007, Annals of the rheumatic diseases.
[172] H. Hoffman. Rilonacept for the treatment of cryopyrin-associated periodic syndromes (CAPS). , 2009, Expert opinion on biological therapy.
[173] R. Flores,et al. Sustained IL‐1α, IL‐4, and IL‐6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus , 2008, Pediatric diabetes.
[174] S. M. McFarlane,et al. Differential activation of nuclear factor‐κB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorly , 2002, FEBS letters.
[175] Valentin A. Pavlov,et al. The cholinergic anti-inflammatory pathway , 2005, Brain, Behavior, and Immunity.
[176] E. Sohar,et al. FAMILIAL MEDITERRANEAN FEVER , 1959, Definitions.
[177] Marlene Wolf,et al. Chemokines: multiple levels of leukocyte migration control. , 2004, Trends in immunology.
[178] M. Mattson,et al. Roles for NF-κB in nerve cell survival, plasticity, and disease , 2006, Cell Death and Differentiation.
[179] H. Arias,et al. The role of inflammation in Alzheimer's disease. , 2005, The international journal of biochemistry & cell biology.
[180] Bin Liu,et al. Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.
[181] S. Targan,et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.
[182] E. Hirsch,et al. Neuroinflammation in Parkinson's disease: a target for neuroprotection? , 2009, The Lancet Neurology.
[183] B. Koller,et al. Genetic Loss of Murine Pyrin, the Familial Mediterranean Fever Protein, Increases Interleukin-1β Levels , 2012, PloS one.
[184] P. Venge,et al. Identification of IL-5 and RANTES as the major eosinophil chemoattractants in the asthmatic lung. , 1996, The Journal of allergy and clinical immunology.
[185] J. Bijzet,et al. Specific glycosylation of α1-acid glycoprotein characterises patients with familial Mediterranean fever and obligatory carriers of MEFV , 2001, Annals of the rheumatic diseases.
[186] J. Cano,et al. The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh‐TNF‐α, IL‐1β and IFN‐γ , 2002 .
[187] K. Biber,et al. Neuron-microglia signaling: Chemokines as versatile messengers , 2008, Journal of Neuroimmunology.
[188] J. Nutt,et al. Neuroimmunophilin ligands in the treatment of Parkinson's disease. , 2002, Current opinion in pharmacology (Print).
[189] Y. Mizuno,et al. Inflammation and infection in Parkinson's disease. , 2006, Histology and histopathology.
[190] T. Hara,et al. Tumour necrosis factor receptor-associated periodic syndrome with a novel mutation in the TNFRSF1A gene in a Japanese family , 2003, European Journal of Pediatrics.
[191] K. Lim,et al. Genetic models of Parkinson disease. , 2009, Biochimica et biophysica acta.
[192] α-Synuclein and Neuronal Cell Death , 2012, Molecular Neurobiology.
[193] G. Hitman,et al. Abnormal tumor necrosis factor receptor I cell surface expression and NF-kappaB activation in tumor necrosis factor receptor-associated periodic syndrome. , 2008, Arthritis and rheumatism.
[194] J. Relton,et al. Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. , 2008, Brain : a journal of neurology.
[195] I. Manabe,et al. Macrophages and islet inflammation in type 2 diabetes , 2013, Diabetes, obesity & metabolism.
[196] G. Hitman,et al. Linkage of familial Hibernian fever to chromosome 12p13. , 1998, American journal of human genetics.
[197] M. D'Andrea,et al. Astrocytes accumulate Aβ42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains , 2003, Brain Research.
[198] U. V. von Andrian,et al. CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. , 2012, Immunity.
[199] B. Chromy,et al. Amyloid-beta peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. , 1998, Brain research.
[200] P. Spano,et al. Distinct roles of diverse nuclear factor-kappaB complexes in neuropathological mechanisms. , 2006, European journal of pharmacology.
[201] A. Yamada,et al. Release of soluble tumor necrosis factor receptor 1 from corneal epithelium by TNF-alpha-converting enzyme-dependent ectodomain shedding. , 2009, Investigative ophthalmology & visual science.
[202] C. Dinarello,et al. IL-37: a new anti-inflammatory cytokine of the IL-1 family. , 2011, European cytokine network.
[203] P. Hawkins,et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.
[204] L. Tartaglia,et al. Two TNF receptors. , 1992, Immunology today.
[205] G. Šimić,et al. nNOS Expression in Reactive Astrocytes Correlates with Increased Cell Death Related DNA Damage in the Hippocampus and Entorhinal Cortex in Alzheimer's Disease , 2000, Experimental Neurology.
[206] H. Vanderstichele,et al. An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-α , 2001, Neurochemistry International.
[207] Gerrit Schlippe,et al. Non-invasive skin biomarkers quantification of psoriasis and atopic dermatitis: cytokines, antioxidants and psoriatic skin auto-fluorescence. , 2012, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[208] H. Erdem,et al. Immunopathogenesis of Behçet’s disease with special emphasize on the possible role of antigen presenting cells , 2007, Rheumatology International.
[209] S. Lorenzl,et al. Minocycline enhances MPTP toxicity to dopaminergic neurons , 2003, Journal of neuroscience research.
[210] C. Dodé,et al. Failure of anti-TNF therapy in TNF Receptor 1-Associated Periodic Syndrome (TRAPS). , 2007, Rheumatology.
[211] Bharat B. Aggarwal,et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin , 1984, Nature.
[212] Ninds Net-Pd Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. , 2006 .
[213] F. Dammacco,et al. Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. , 1999, Arthritis and rheumatism.
[214] J. Stow,et al. Cytokine secretion in macrophages and other cells: pathways and mediators. , 2009, Immunobiology.
[215] Y. Fukuda,et al. Interleukin-13 induces thymus and activation-regulated chemokine (CCL17) in human peripheral blood mononuclear cells. , 2002, Cytokine.
[216] D. Kastner,et al. The TNF Receptor-Associated Periodic Syndrome (TRAPS): Emerging Concepts of an Autoinflammatory Disorder , 2002, Medicine.
[217] C. Nathan,et al. Shedding of tumor necrosis factor receptors by activated human neutrophils , 1990, The Journal of experimental medicine.
[218] M. Mattson. NF-kappaB in the survival and plasticity of neurons. , 2005, Neurochemical research.
[219] S. Akira,et al. Correction: Stat3 Activation Is Responsible for IL-6–Dependent T Cell Proliferation through Preventing Apoptosis: Generation and Characterization of T Cell–Specific Stat3-Deficient Mice , 2015, The Journal of Immunology.
[220] D. Goeddel,et al. Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.
[221] Myung-Shik Lee. Cytokine synergism in apoptosis: its role in diabetes and cancer. , 2002, Journal of biochemistry and molecular biology.
[222] J. Wegiel,et al. Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease , 2004, Neurobiology of Aging.
[223] M. D. Turner,et al. Tumour necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion , 2011, Bioscience reports.
[224] P. Taupin. Adult neurogenesis pharmacology in neurological diseases and disorders , 2008, Expert review of neurotherapeutics.
[225] B. Medoff,et al. IFN-γ-Inducible Protein 10 (CXCL10) Contributes to Airway Hyperreactivity and Airway Inflammation in a Mouse Model of Asthma1 , 2002, The Journal of Immunology.
[226] G. Hitman,et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. , 2009, Arthritis and rheumatism.
[227] P. Halban,et al. Cytokine production by islets in health and diabetes: cellular origin, regulation and function , 2010, Trends in Endocrinology & Metabolism.
[228] Makoto Sawada,et al. Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains , 2003, Acta Neuropathologica.
[229] C. Jacque,et al. Identification and topography of neuronal cell populations expressing TNF alpha and IL-1 alpha in response to hippocampal lesion. , 1996, Journal of neuroscience research.
[230] H. Gendelman,et al. Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons , 2008, PloS one.
[231] J. Grant-Kels,et al. Infantile Generalized Pustular Psoriasis Associated With Lytic Lesions of the Bone , 1993, Pediatric dermatology.
[232] L. Cosmi,et al. IL-1 and T Helper Immune Responses , 2013, Front. Immunol..
[233] H. Boddeke,et al. Neuronal Chemokines: Versatile Messengers In Central Nervous System Cell Interaction , 2007, Molecular Neurobiology.
[234] H. Gendelman,et al. CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease , 2007, Journal of Neuroimmunology.
[235] Anthony H V Schapira,et al. Neurobiology and treatment of Parkinson's disease. , 2009, Trends in pharmacological sciences.
[236] J. Toro,et al. Autoinflammatory diseases: clinical and genetic advances. , 2008, Archives of dermatology.
[237] J. Trowsdale,et al. Structural basis for PRYSPRY-mediated tripartite motif (TRIM) protein function , 2007, Proceedings of the National Academy of Sciences.
[238] E. Leonard,et al. Neutrophil attractant/activation protein-1 (NAP-1 [interleukin-8]). , 1990, American journal of respiratory cell and molecular biology.
[239] D. Huster,et al. The influence of glycosaminoglycans on IL-8-mediated functions of neutrophils. , 2012, Carbohydrate research.
[240] V. Bonifati. LRRK2 Low-penetrance Mutations (Gly2019Ser) and Risk Alleles (Gly2385Arg)—Linking Familial and Sporadic Parkinson’s Disease , 2007, Neurochemical Research.
[241] P. Rutgeerts,et al. Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future , 2013, Alimentary pharmacology & therapeutics.
[242] P. Mander,et al. Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration , 2002, Neuroscience.
[243] Ian Todd,et al. Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes , 1999, Cell.
[244] K. Rajarathnam,et al. Monomeric and Dimeric CXCL8 Are Both Essential for In Vivo Neutrophil Recruitment , 2010, PloS one.
[245] M. Herrero,et al. Parkinson's disease and inflammatory changes , 2009, Neurotoxicity Research.
[246] S. Paul,et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.
[247] R. Shivers,et al. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. , 2004, Histology and histopathology.
[248] S. Barger,et al. S100β Induction of the Proinflammatory Cytokine Interleukin‐6 in Neurons , 2000, Journal of neurochemistry.
[249] D J Rowlands,et al. A multi-centre randomised controlled trial of minimally invasive direct coronary bypass grafting versus percutaneous transluminal coronary angioplasty with stenting for proximal stenosis of the left anterior descending coronary artery. , 2004, Health technology assessment.
[250] Juliet M. Taylor,et al. Neuroinflammation and oxidative stress: Co-conspirators in the pathology of Parkinson’s disease , 2013, Neurochemistry International.
[251] R. Goldbach-Mansky,et al. Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. , 2010, Clinical immunology.
[252] George Kollias,et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor , 1995, Cell.
[253] D. Goeddel,et al. Prevention of constitutive TNF receptor 1 signaling by silencer of death domains. , 1999, Science.
[254] P. Lev,et al. Abnormal regulation of soluble and anchored IL-6 receptor in monocytes from patients with essential thrombocythemia. , 2010, Experimental hematology.
[255] Scott Carver,et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action , 2003, Nature Medicine.
[256] T. Wright,et al. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. , 1999, The Journal of clinical investigation.
[257] G. G. Stokes. "J." , 1890, The New Yale Book of Quotations.
[258] Tapan P. Patel,et al. Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death , 2011, Neuron.
[259] L. Lue,et al. Involvement of Microglial Receptor for Advanced Glycation Endproducts (RAGE) in Alzheimer's Disease: Identification of a Cellular Activation Mechanism , 2001, Experimental Neurology.
[260] Richard J Smeyne,et al. Allopregnanolone Reinstates Tyrosine Hydroxylase Immunoreactive Neurons and Motor Performance in an MPTP-Lesioned Mouse Model of Parkinson's Disease , 2012, PloS one.
[261] T. Taniguchi,et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.
[262] B. Dewald,et al. Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate , 2004, Rheumatology International.
[263] P. Mcgeer,et al. R-(−)-Deprenyl Inhibits Monocytic THP-1 Cell Neurotoxicity Independently of Monoamine Oxidase Inhibition , 2000, Experimental Neurology.
[264] M. Turner,et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. , 1988, Clinical and experimental immunology.
[265] M. Kumar,et al. Anti-inflammatory treatments for chronic diseases: a review. , 2013, Inflammation & allergy drug targets.
[266] L. Moreland. Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. , 1999, Cleveland Clinic journal of medicine.
[267] A. Bakkaloğlu,et al. Mutations in the gene for familial Mediterranean fever: do they predispose to inflammation? , 2003, The Journal of rheumatology.
[268] A. Fischer,et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. , 2002, American journal of human genetics.
[269] A. Osterhaus,et al. Vγ9Vδ2 T cells recovered from eyes of patients with Behçet's disease recognize non-peptide prenyl pyrophosphate antigens , 2002, Journal of Neuroimmunology.
[270] H. Loetscher,et al. Tumor necrosis factor receptors-structure and function , 1992, Immunologic research.
[271] C. Gabay,et al. IL‐1, IL‐18, and IL‐33 families of cytokines , 2008, Immunological reviews.
[272] D. Männel,et al. The TNF-TNF receptor system. , 2002, Biological chemistry.
[273] L. Petruzzelli,et al. Signaling Pathways Involved in IL-8-Dependent Activation of Adhesion Through Mac-11 , 2002, The Journal of Immunology.
[274] L. Hassman,et al. Pulmonary Chemokine Expression Is Coordinately Regulated by STAT1, STAT6, and IFN-γ , 2004, The Journal of Immunology.
[275] M. McDermott,et al. Familial Mediterranean fever and related periodic fever syndromes/autoinflammatory diseases , 2012, Current opinion in rheumatology.
[276] S. Rose-John,et al. The importance of shedding of membrane proteins for cytokine biology. , 2000, European cytokine network.
[277] C. Dinarello,et al. Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.
[278] H. Inoko,et al. Immunology and functional genomics of Behçet's disease , 2003, Cellular and Molecular Life Sciences CMLS.
[279] Y. Suh,et al. Minocycline and neurodegenerative diseases , 2009, Behavioural Brain Research.
[280] G. Bing,et al. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration , 2003, Neurobiology of Disease.
[281] C. Jackson,et al. Western ALS Study Group , 2004, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases.
[282] M. Giedlin,et al. IL-8 induces neutrophil chemotaxis predominantly via type I IL-8 receptors. , 1995, Journal of immunology.
[283] C. Hogaboam,et al. Chemokines in allergic aspergillosis--from animal models to human lung diseases. , 2006, Inflammation & allergy drug targets.
[284] M. Humbert,et al. Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. , 1999, Journal of immunology.
[285] H. Ellingsgaard,et al. Low Concentration of Interleukin-1β Induces FLICE-Inhibitory Protein–Mediated β-Cell Proliferation in Human Pancreatic Islets , 2006, Diabetes.
[286] J. Paović,et al. Behcet's Disease: Systemic and Ocular Manifestations , 2013, BioMed research international.
[287] J. Sanderson,et al. Role of γδ T cells in pathogenesis and diagnosis of Behçet's disease , 1996, The Lancet.
[288] E. Borroni,et al. Shaping the gradient by nonchemotactic chemokine receptors , 2009, Cell adhesion & migration.
[289] J. Rogers,et al. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. , 2000, Brain research. Molecular brain research.
[290] C. Browning,et al. Signalling by CXC‐chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPγS binding induced by IL‐8 and GROα , 1999, British journal of pharmacology.
[291] D. Wakefield,et al. The role of cytokines in the pathogenesis of inflammatory eye disease. , 1992, Cytokine.
[292] A. Hamzaoui,et al. Abnormal expression of chemokine receptors in Behçet's disease: relationship to intracellular Th1/Th2 cytokines and to clinical manifestations. , 2004, Journal of autoimmunity.
[293] T. Klockgether,et al. Neuronal and Glial Coexpression of Argininosuccinate Synthetase and Inducible Nitric Oxide Synthase in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.
[294] C. Montecucco,et al. Role of chemokines and chemokine receptors in regulating specific leukocyte trafficking in the immune/inflammatory response. , 2003, Clinical and experimental rheumatology.
[295] W. Zou,et al. Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis. , 2007, American journal of physiology. Cell physiology.
[296] G. Hitman,et al. Differential cytokine secretion results from p65 and c-Rel NF-κB subunit signaling in peripheral blood mononuclear cells of TNF receptor-associated periodic syndrome patients. , 2011, Cellular immunology.
[297] A. Członkowska,et al. Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease. , 2004, International immunopharmacology.
[298] Serdar Balci,et al. Phenotype 2 Familial Mediterranean Fever: Evaluation of 22 Case Series and Review of the Literature on Phenotype 2 FMF , 2013, Renal failure.
[299] Nicole Nelson,et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-α from cells , 1997, Nature.
[300] T. Wyss-Coray,et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. , 2003, Nature medicine.
[301] Shunichiro Shinagawa,et al. Increase in the IgG avidity index due to herpes simplex virus type 1 reactivation and its relationship with cognitive function in amnestic mild cognitive impairment and Alzheimer's disease. , 2013, Biochemical and biophysical research communications.
[302] F. L. Saux,et al. Identification and topography of neuronal cell populations expressing; TNFα and IL‐1α in response to hippocampal lesion , 1996 .
[303] G. D'Haens,et al. Recent developments in the treatment of inflammatory bowel disease , 2013, Journal of digestive diseases.
[304] J. Flier,et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation , 2001, The Journal of pathology.
[305] P. Toghill,et al. Familial Hibernian fever. , 1982, The Quarterly journal of medicine.
[306] R. Dwek,et al. Glycosylation of interleukin-6 purified from normal human blood mononuclear cells. , 1992, European journal of biochemistry.
[307] T. Jin,et al. Fluorescence Resonance Energy Transfer Imaging Reveals that Chemokine-Binding Modulates Heterodimers of CXCR4 and CCR5 Receptors , 2008, PloS one.
[308] H. Erdem,et al. Serum interleukin-18 levels in patients with Behçet’s disease. Is its expression associated with disease activity or clinical presentations? , 2006, Rheumatology International.
[309] S. Akira,et al. Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. , 1998, Journal of immunology.
[310] R. Maizels,et al. IL-6 controls susceptibility to helminth infection by impeding Th2 responsiveness and altering the Treg phenotype in vivo , 2013, European journal of immunology.
[311] P. Magistretti,et al. The role of astroglia in neuroprotection , 2009, Dialogues in clinical neuroscience.
[312] D. Sillence,et al. Gene localization for an autosomal dominant familial periodic fever to 12p13. , 1998, American journal of human genetics.
[313] P. Tak,et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. , 2008, Pharmacology & therapeutics.
[314] P. Gregersen,et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. , 2009, The New England journal of medicine.
[315] S. Davis,et al. What can rodent models tell us about cognitive decline in alzheimer’s disease? , 2003, Molecular Neurobiology.
[316] S. Rose-John,et al. Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. , 1998, Blood.
[317] T. Imai,et al. Chemokines as Novel Therapeutic Targets for Inflammatory Bowel Disease , 2009, Annals of the New York Academy of Sciences.
[318] Sulagna Das,et al. Inflammation: A new candidate in modulating adult neurogenesis , 2008, Journal of neuroscience research.
[319] J. Ahluwalia. Immunotherapy in inflammatory bowel disease. , 2012, The Medical clinics of North America.
[320] J. Bradley,et al. TNF‐mediated inflammatory disease , 2008, The Journal of pathology.
[321] A. Schapira. Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease , 2009, Neurology.
[322] G. Firestein,et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist , 2004, The Lancet.
[323] M. O’Banion,et al. Regulation of prostaglandin E2 synthesis after brain irradiation. , 2005, International journal of radiation oncology, biology, physics.
[324] J. Natvig,et al. The Chemokines CCL5, CCL2 and CXCL12 Play Significant Roles in the Migration of Th1 Cells into Rheumatoid Synovial Tissue , 2003, Scandinavian journal of immunology.
[325] Gregory Jicha,et al. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease , 2012, Alzheimer's & Dementia.
[326] L. O’Neill,et al. The interleukin‐1 receptor/Toll‐like receptor superfamily: 10 years of progress , 2008, Immunological reviews.